The study is researching an experimental drug called odronextamab. The study is for patients with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma). In this study, we want to find out more about how safe and tolerable the study drug is. We will also compare how well the study drug orks compared to rituximab and chemotherapy (the current standard of care for NHL).

Examine the validity and reliability of UTRS in the assessment of essential tremor (ET) and Parkinson tremor.

Researchers at the University of North Carolina at Chapel Hill are studying innovative ways to promote healthy eating, physical activity, and weight loss in young adults using a smartphone app, digital health tools, and daily messaging. We are seeking volunteers to enroll in a 6-month research study that tests a smartphone-delivered weight loss program designed specifically for young adults.

The purpose of this research study is to explore benefits of workplace social connection following coffee meetups with colleagues. Must be a full-time UNC employee to participate.

Have you been recently diagnosed with Acute Lymphoblastic Leukemia? If so, you may be able to take part in a research study to help us learn more about the effects of using Tyrosine Kinase Inhibitor (TKI), steroids and blinatumomab versus treatment with steroids, Tyrosine Kinase Inhibitor (TKI) and chemotherapy.

Do you have stage 1, HER2-positive breast cancer? Has your surgery already been completed? If so, you may be able to take part in a study to help us learn more about a combination of medications to treat your cancer.

Do you have metastatic or recurrent lung cancer? Have you already been treated with chemotherapy or immunotherapy? If so, you may qualify for the LungMap protocol, which will help us identify clinical trials you may be eligible for.

Do you plan to undergo radiation therapy for a cancer in the abdomen or pelvic region? You may be able to take part in a research study to help us learn if a fatty acid supplement can improve quality of life by limiting GI upset during radiation therapy.

To evaluate the safety and efficacy of BLU-222 therapy in patients with advanced solid tumors.

Do you have small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer, or gastroenteropancreatic neuroendocrine carcinomas? Have you been treated with existing standard of care treatments that did not work? You may be able to take part in a research study to test a new drug for these types of cancer.